PTACH [NCH 51]

CHF 90.00
In stock
AG-CR1-3667-M0055 mgCHF 90.00
AG-CR1-3667-M02525 mgCHF 320.00
 
More Information
Product Details
Synonyms Cpd 51; S-(7-Oxo-7-((4-phenylthiazol-2-yl)amino)heptyl) 2-methylpropanethioate
Product Type Chemical
Properties
Formula C20H26N2O2S2
MW 390.56
CAS 848354-66-5
Purity Chemicals ≥97% (HPLC)
Appearance White crystals.
Solubility Soluble in DMSO (25mg/ml) or ethanol (10mg/ml). Insoluble in water.
Identity Determined by 1H-NMR.
InChi Key MDYDGUOQFUQOGE-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent non-hydroxamate HDAC inhibitor (HDACi) (IC50: 32, 48 and 41nM for HDAC4, HDAC1 and HDAC6, respectively).
  • Cell permeable prodrug that is intracellularly converted to the potent HDAC inhibitor NCH 31.
  • Predicted to exhibit a similar HDAC binding mode as that of SAHA, interacting with the active-site zinc targeting group.
  • Shown to exhibit comparable antiproliferative and apoptotic activity as SAHA against various cancer cell lines. Inhibits growth of various cancer cells in vitro (EC50=1.1 - 9.1μM).
  • Reactivates latent HIV-1 gene expression.
  • Active against selected neurodevelopmental disorders.
Product References
  1. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates: T. Suzuki, et al.; J. Med. Chem. 48, 1019 (2005)
  2. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells: T. Sanda, et al.; Leukemia 21, 2344 (2007)
  3. Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor: T. Suzuki, et al.; Bioorg. Med. Chem. Lett. 17, 1558 (2007)
  4. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression: A.F. Victoriano, et al.; FEBS Lett. 585, 1103 (2011)
  5. Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients? M. Martinez-Bonet, et al.; J. Virus Erad. 1, 148 (2015)
  6. Altered neuronal network and rescue in a human MECP2 duplication model: S. Nageshappa, et al.; Mol. Psychiatry 21, 178 (2016)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.